299 related articles for article (PubMed ID: 33122737)
21. Prognostic significance of
Li B; Zou D; Yang S; Ouyang G; Mu Q
J Int Med Res; 2020 Mar; 48(3):300060519891013. PubMed ID: 31826693
[TBL] [Abstract][Full Text] [Related]
22. Incidence and prognostic impact of U2AF1 mutations and other gene alterations in myelodysplastic neoplasms with isolated 20q deletion.
Castillo MI; Ribate VE; Muñoz CM; Santillana SG; Taboada SE; Casterá ME; Abinzano CMJ; Barranco IA; Nieto CR; Pampliega VM; Blanco ML; de Andrés ÁS; de Oteyza PJ; Del Castillo BT; Font GI; Cayuela JA; Díez-Campelo M; Sánchez AR; Vercet SC; Díaz TM;
Cancer Med; 2023 Aug; 12(16):16788-16792. PubMed ID: 37403747
[TBL] [Abstract][Full Text] [Related]
23. Analysis of gene mutation characteristics and its correlation with prognosis in patients with myelodysplastic syndromes.
Yang X; Zhao H; Wu H; Guo X; Jia H; Liu W; Wei Y; Can C; Ma D
Clin Chim Acta; 2024 Feb; 554():117789. PubMed ID: 38246208
[TBL] [Abstract][Full Text] [Related]
24. Impact of single versus multiple spliceosome mutations on myelodysplastic syndrome.
Nagehan P; Sabbir M; Song J; Mohammad H
J Clin Exp Hematop; 2023; 63(3):173-176. PubMed ID: 37766563
[TBL] [Abstract][Full Text] [Related]
25. Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations.
Ohgami RS; Ma L; Merker JD; Gotlib JR; Schrijver I; Zehnder JL; Arber DA
Mod Pathol; 2015 May; 28(5):706-14. PubMed ID: 25412851
[TBL] [Abstract][Full Text] [Related]
26. [The Correlation of Gene Mutation and Clinical Characteristics in Patients with Myelodysplastic Syndrome and Prognostic Analysis].
Zhang WW; Zhang YL; Ren CC; Wu TK; Liu B
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):176-183. PubMed ID: 38387918
[TBL] [Abstract][Full Text] [Related]
27. U2AF1 mutations alter sequence specificity of pre-mRNA binding and splicing.
Okeyo-Owuor T; White BS; Chatrikhi R; Mohan DR; Kim S; Griffith M; Ding L; Ketkar-Kulkarni S; Hundal J; Laird KM; Kielkopf CL; Ley TJ; Walter MJ; Graubert TA
Leukemia; 2015 Apr; 29(4):909-17. PubMed ID: 25311244
[TBL] [Abstract][Full Text] [Related]
28. Co-mutation landscape and clinical significance of RAS pathway related gene mutations in patients with myelodysplastic syndrome.
Ren Y; Lang W; Mei C; Luo Y; Ye L; Wang L; Zhou X; Xu G; Ma L; Jin J; Tong H
Hematol Oncol; 2023 Feb; 41(1):159-166. PubMed ID: 36316121
[TBL] [Abstract][Full Text] [Related]
29. [Analysis of ASXL1 gene variant in patients with myelodysplastic syndrome].
Chen M; Liu J; Chao H; Qin W; Jiang N; Lu X; Cen L; Jiang Y; Cai X; Zhang R; Wang Q
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2020 Feb; 37(2):110-115. PubMed ID: 32034733
[TBL] [Abstract][Full Text] [Related]
30. Ribosome biogenesis is a downstream effector of the oncogenic U2AF1-S34F mutation.
Akef A; McGraw K; Cappell SD; Larson DR
PLoS Biol; 2020 Nov; 18(11):e3000920. PubMed ID: 33137094
[TBL] [Abstract][Full Text] [Related]
31. Mutation status and burden can improve prognostic prediction of patients with lower-risk myelodysplastic syndromes.
Jiang L; Luo Y; Zhu S; Wang L; Ma L; Zhang H; Shen C; Yang W; Ren Y; Zhou X; Mei C; Ye L; Xu W; Yang H; Lu C; Jin J; Tong H
Cancer Sci; 2020 Feb; 111(2):580-591. PubMed ID: 31804030
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of U2AF1 mutant in patients with de novo myelodysplastic syndromes: a meta-analysis.
Wang H; Zhang N; Wu X; Zheng X; Ling Y; Gong Y
Ann Hematol; 2019 Dec; 98(12):2629-2639. PubMed ID: 31754743
[TBL] [Abstract][Full Text] [Related]
33. Association of Somatic Gene Mutations with Risk of Transformation into Acute Myeloid Leukemia in Patients with Myelodysplastic Syndrome: A Systematic Review and Meta-Analysis.
Sutandyo N; Mulyasari R; Kosasih A; Rinaldi I; Louisa M; Kevinsyah AP; Winston K
Asian Pac J Cancer Prev; 2022 Apr; 23(4):1107-1116. PubMed ID: 35485665
[TBL] [Abstract][Full Text] [Related]
34. Clinical features and biological implications of different U2AF1 mutation types in myelodysplastic syndromes.
Li B; Liu J; Jia Y; Wang J; Xu Z; Qin T; Shi Z; Song Z; Peng S; Huang H; Fang L; Zhang H; Pan L; Hu N; Qu S; Zhang Y; Wu J; Liu N; Ru K; Huang G; Xiao Z
Genes Chromosomes Cancer; 2018 Feb; 57(2):80-88. PubMed ID: 29057546
[TBL] [Abstract][Full Text] [Related]
35. Mutations of myelodysplastic syndromes (MDS): An update.
Ganguly BB; Kadam NN
Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
[TBL] [Abstract][Full Text] [Related]
36. Distinct genetic landscapes and their clinical implications in younger and older patients with myelodysplastic syndromes.
Lee WH; Lin CC; Wang YH; Yao CY; Kuo YY; Tseng MH; Peng YL; Hsu CA; Sun HI; Chuang YK; Hsu CL; Tien FM; Tsai CH; Chou WC; Hou HA; Tien HF
Hematol Oncol; 2023 Aug; 41(3):463-473. PubMed ID: 36420747
[TBL] [Abstract][Full Text] [Related]
37. Predictive and prognostic value of gene mutations in myelodysplastic syndrome treated with hypomethylating agents: a meta-analysis.
Hu C; Wang X
Leuk Lymphoma; 2022 Oct; 63(10):2336-2351. PubMed ID: 35543621
[TBL] [Abstract][Full Text] [Related]
38. The Genetics of Myelodysplastic Syndromes: Clinical Relevance.
Chiereghin C; Travaglino E; Zampini M; Saba E; Saitta C; Riva E; Bersanelli M; Della Porta MG
Genes (Basel); 2021 Jul; 12(8):. PubMed ID: 34440317
[TBL] [Abstract][Full Text] [Related]
39. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes.
Sallman DA; Komrokji R; Vaupel C; Cluzeau T; Geyer SM; McGraw KL; Al Ali NH; Lancet J; McGinniss MJ; Nahas S; Smith AE; Kulasekararaj A; Mufti G; List A; Hall J; Padron E
Leukemia; 2016 Mar; 30(3):666-73. PubMed ID: 26514544
[TBL] [Abstract][Full Text] [Related]
40. Myelodysplastic neoplasm-associated U2AF1 mutations induce host defense defects by compromising neutrophil chemotaxis.
Gurule NJ; Malcolm KC; Harris C; Knapp JR; O'Connor BP; McClendon J; Janssen WJ; Lee FFY; Price C; Osaghae-Nosa J; Wheeler EA; McMahon CM; Pietras EM; Pollyea DA; Alper S
Leukemia; 2023 Oct; 37(10):2115-2124. PubMed ID: 37591942
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
